A summary of IPOs from companies in the biotech and pharma world since May 1, 2019.
May 2019 IPO Filings and Pricings, Updated 5/23/19
Know of an IPO since May 1, 2019, that we missed? Email us at news@biospace.com.
Related: Check out BioSpace’s January list, February list, March list, and April list.
| Date | Company Name | Amount (USD) | Company HQ | Research Focus |
|---|---|---|---|---|
| 5/22/19 | Bicycle Therapeutics | $60.6M Priced | Cambridge, UK | Exosome therapeutics in I/O and infectious diseases |
| 5/22/19 | Biophytis | $15M Filed | Paris, France | Novel therapeutics that slow down the degenerative processes associated with aging |
| 5/13/19 | Applied Therapeutics | $40M Priced | New York City, NY | Cutting-edge technology to validated drug targets in areas of high unmet medical need |
| 5/8/19 | Axcella | $71.4M Priced | Cambridge, MA | AXA Development Platform to harness power of endogenous metabolic modulators (EMMS) |
| 5/8/19 | Milestone Pharmaceuticals | $82.5M Priced | Montreal, Quebec, Canada | Developing and commercializing etripamil for the treatment of cardiovascular indications |
| 5/8/19 | NextCure | $75M Priced | Beltsville, MD | Immunomedicines to treat cancer and other immune-related diseases |
| 5/8/19 | Cortexyme | $75M Priced | South San Francisco, CA | Novel treatments for altering the course of neurodegenerative diseases |
| 5/7/19 | Trevi Therapeutics | $55M Priced | New Haven, CT | Nalbuphine ER to treat serious neurologically mediated conditions |
| 5/2/19 | TransMedics | $91.1M Priced | Andover, MA | Organ transplant therapy for end-stage organ failure patients across multiple disease states |
